Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) said management will host an audio webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to discuss fourth-quarter and full-year fiscal 2025 results (fiscal year ended September 30, 2025) and provide an operations and strategy update.
The company will issue a news release and presentation materials with summary financial information prior to the call. The live webcast and a replay will be available at www.bd.com/investors.
BD (NYSE: BDX) announced enrollment of the first patient in the XTRACT™ Registry on September 29, 2025, a prospective, multi-center, single-arm post-market study to evaluate real-world performance of the Rotarex™ Catheter System for peripheral artery disease (PAD).
The registry plans up to 600 patients across as many as 100 U.S. sites with follow-ups at 30 days, 6 months, and 12 months to assess safety and effectiveness. The Rotarex catheter offers combined atherectomy and thrombectomy mechanisms to remove plaque and thrombus. BD said the registry will generate real-world evidence to inform clinical decision-making and treatment strategies for PAD.
BD (NYSE: BDX) and Opentrons announced a multi-year collaboration on Oct 8, 2025 to integrate Opentrons robotic liquid-handling into BD single-cell multiomics instruments.
The partnership intends to integrate the BD Rhapsody System with the Opentrons Flex platform, develop verified protocols, and build an automation-compatible module to automate next-generation sequencing library preparation and cell capture, enabling hands-free workflows and scaling to million-cell studies.
Early access opportunities will be available and both companies will present details at the ASHG Annual Meeting, Oct 14–18, 2025 (BD Booth 447; Opentrons Booth 635).
BD (NYSE: BDX) celebrates 55 years of manufacturing at its Sumter, South Carolina facility on Oct. 3, 2025. The site began in 1970 with 25 employees and now spans >600,000 square feet, employs ~900 associates and produces billions of products annually, including BD Vacutainer® blood collection products that the company says care for 84 patients every second.
Since FY21, BD invested more than $90 million in Sumter, tripled year-over-year investment from FY24 to FY25, and plans to invest ~$30 million in FY26 for modernization, new lines and training. BD announced a $10,000 donation to the Tuomey Foundation and contributes >$100,000 annually to local organizations. BD operates >30 U.S. manufacturing and distribution sites across 17 states and Puerto Rico, employing >10,000 people.
BD (NYSE: BDX) has announced a groundbreaking pharmacy automation partnership with Henry Ford Health to revolutionize medication storage and prescription delivery. The collaboration centers on implementing the BD Rowa™ Vmax, a sophisticated pharmacy automation robot, across Henry Ford Health's hospital-based community pharmacies in Southeast and Central Michigan.
The partnership will enable 24/7 prescription access for patients and features automated high-capacity storage for safe and accurate prescription retrieval. This innovative system, already widely used in Europe, will allow pharmacy staff to focus on higher-value patient care tasks while improving operational efficiency. The implementation includes capabilities for real-time prescription tracking and can accommodate refrigerated medications, supplies, and over-the-counter products.
BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.
The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.
BD (NYSE: BDX) has launched the Love Your Limbs™ PAD Community Screening Initiative to combat Peripheral Artery Disease (PAD), a circulatory disorder affecting over 21 million Americans and 200 million people globally. The initiative offers free ankle-brachial index screenings in partnership with physicians to detect PAD early.
The company is developing a PAD Health Access Dashboard and Heatmap to identify high-need communities and is partnering with organizations like Ochsner Health and The Way to My Heart. BD is also supporting the American Heart Association's National PAD Action Plan to increase awareness and improve early diagnosis of PAD, which causes over 150,000 preventable amputations annually in the U.S.
BD (NYSE:BDX), a leading global medical technology company, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference. The company's presentation is scheduled for Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time.
Investors and interested parties can access the live webcast of the presentation through BD's investor relations website at investors.bd.com. A replay will be made available on the same platform after the event concludes.
BD (NYSE:BDX) reported strong Q3 fiscal 2025 results with revenue reaching $5.5 billion, up 10.4% as reported and 3.0% organic. The company delivered significant earnings growth with adjusted diluted EPS of $3.68, up 5.1%. Notably, BD raised its full-year adjusted EPS guidance to $14.30-$14.45, reflecting 9.4% growth at the midpoint.
Key segment performance included BD Medical growing 14.4%, BD Life Sciences declining 0.5%, and BD Interventional increasing 7.2%. The company announced plans to combine its Biosciences & Diagnostic Solutions business with Waters Corporation and expects to complete the remaining $250 million of its $1 billion share buyback by fiscal year-end.
Gross margin improved significantly, with GAAP margin up 160 basis points and adjusted margin up 50 basis points, driven by BD Excellence initiatives. The company maintained its organic revenue growth guidance of 3.0-3.5% for fiscal 2025.
BD (NYSE: BDX), a leading medical technology company, has achieved a significant milestone as its Urology and Critical Care (UCC) and Surgery business units became the first in the medical technology industry to receive the diamond-level rating across all seven supply chain resilience domains from the Healthcare Industry Resilience Collaborative (HIRC).
The achievement follows a rigorous audit process evaluating multiple areas including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management, and operational health. This recognition builds upon BD's previous Transparency Partner Badge received in 2023 and reflects the company's ongoing investments in supply chain and manufacturing operations improvements.